Align Technology Inc. (ALGN) is a leading, global medical device company that has revolutionized the orthodontic industry with its innovative products. Formally incorporated in 1997, the San Jose, California-based company is renowned for designing, manufacturing, and marketing the Invisalign system, which treats the misalignment of teeth, also known as malocclusion.
This state-of-the-art system, unlike traditional braces, employs a series of custom-made, clear plastic aligners that gradually shift teeth into place. This groundbreaking concept brought forth a new, more aesthetic alternative to traditional wire and bracket braces, and has helped millions worldwide to attain better smiles without the accompanied discomfort and self-consciousness.
Align Technology leverages cutting-edge technology and employs software tools, standardized data management and analysis, CAD/CAM (computer-aided design and computer-aided manufacturing), and 3D printing. This unique integration of healthcare and technology has positioned the company at the forefront of medical devices, offering innovative solutions to both doctors and patients, and fundamentally changing how orthodontic and restorative treatment is perceived and delivered.
Beyond Invisalign, Align also manufactures and sells iTero Intraoral scanners and services, which provide dental professionals with powerful digital scanning solutions. The iTero scanning systems directly support the Invisalign system's treatment processes, as well as serving general dentistry and restorative oral healthcare.
Align Technology markets its products in multiple countries worldwide, working closely with orthodontists, general practitioner dentists (GPs), and oral surgeons to ensure the broad and effective use of its product offerings.
The company's unwavering commitment to innovation, its partnership with dental professionals, and its deep impact on patients' lives have played a key role in its success. Align Technology continues to develop new technologies and advancements, maintaining a dynamic and progressive corporate culture that is devoted to revolutionizing dental care.
Over the years, Align Technology Inc. has become a remarkable success story, with shares listed on the NASDAQ. This success is attributed not only to the innovation that the company represents but also to the tangible results that their products deliver, effectively combining medical expertise with advanced technology to improve dental treatments, patient comfort, and outcomes.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
This article analyzes the Q2 performance of several dental equipment and technology stocks, highlighting Dentsply Sirona (XRAY), Envista (NVST), Align Technology (ALGN), and Henry Schein (HSIC). It details their revenue growth, performance against analyst estimates, and stock price reactions, noting that the sector experienced strong Q2 revenues but subsequent stock price declines. The piece also touches on broader market shifts, including concerns over AI and geopolitics impacting investor focus.
Align Technology recently presented at the 2026 Global Healthcare Conference, revealing quarterly earnings that exceeded expectations but also lowered Q3 revenue guidance. This dual message highlights ongoing challenges from inflation and delayed elective dental treatments affecting demand for Align's products. The article suggests that investors need to balance short-term caution with a broader perspective on oral care, as the company's near-term performance hinges on a recovery in patient traffic and case starts.
Illumina Inc. has appointed Mike Sullivan as Chief Commercial Officer and Julie Coletti as Chief Legal Officer. These new hires bring extensive leadership experience from the life sciences, diagnostics, and medical technology sectors, aiming to strengthen Illumina's executive team and drive continued growth and customer service.
Align Technology (ALGN), known for its Invisalign system, has seen its stock underperform the healthcare sector despite its strong market position and high profitability. The company's recent weakness is attributed to a slow recovery in the dental market, with patients delaying elective procedures due to inflation and economic uncertainty. Although Q2 2026 results exceeded estimates, a lower Q3 revenue guidance further impacted the stock, leading analysts to maintain a "Moderate Buy" rating with a projected 38% upside.